Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

Celiac Disease Symptoms Vary by Race and Ethnicity

Race- and ethnicity-based disparities in symptom presentation and comorbidity patterns exist among patients with celiac disease.

Locally Advanced Rectal Cancer Responds to HER2 Therapy

Six of eight patients (75%) with HER2-positive rectal adenocarcinoma responded to trastuzumab and tucatinib plus chemotherapy, including four clinical complete responses.

Vitamin C’s Potential Use in Cancer Is Getting a Second Look

Decades after early trials seemed to close the book on vitamin C as a cancer treatment, a member of a group of determined researchers is receiving the therapy himself.

Education Gap Tied to Higher Risk for Young-Onset CRC Death

Researchers analyze trends in colorectal cancer mortality among adults aged 25-49 years in a study spanning about three decades.

Aspirin Unlikely to Cut Colorectal Cancer Incidence

A Cochrane Review finds aspirin likely results in little to no difference in colorectal cancer incidence at a follow-up of 5 years to less than 15 years.

Tumor Genomic Testing: Too Little, Too Late

Tumor genomic testing is critical to informed treatment decisions, but researchers find that it’s used in too few patients and often too late.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

Race- and ethnicity-based disparities in symptom presentation and comorbidity patterns exist among patients with celiac disease.

Six of eight patients (75%) with HER2-positive rectal adenocarcinoma responded to trastuzumab and tucatinib plus chemotherapy, including four clinical complete responses.

Decades after early trials seemed to close the book on vitamin C as a cancer treatment, a member of a group of determined researchers is receiving the therapy himself.

Researchers analyze trends in colorectal cancer mortality among adults aged 25-49 years in a study spanning about three decades.

A Cochrane Review finds aspirin likely results in little to no difference in colorectal cancer incidence at a follow-up of 5 years to less than 15 years.

Tumor genomic testing is critical to informed treatment decisions, but researchers find that it’s used in too few patients and often too late.

News All Time

Symptom-Based H pylori Testing Does Not Prevent Cancer

Most gastric cancers found in people diagnosed with H pylori may already be present at diagnosis, and treatment of the infection may not provide short-term protection.

Evidence Suggest Fewer GLP-1 Doses Maintain Weight Loss

Doctors have started to personalize GLP-1 dosing with surprising outcomes.

Cholera Aid for African Countries Stalled by Iran Conflict

Emergency cholera medical supplies for several African countries have become stuck in a logistical quagmire caused by the Iran war, aid officials told ⁠Reuters, raising...

New GERD Score May Help Clinicians Spot Biggest Symptom

In patients with GERD, dominant symptom intensity is a simple patient-reported measure that identifies the most burdensome symptom and tracks treatment response.

Can a Machine Learning Model Predict Liver Cancer?

Using routine clinical data, the model gauges liver cancer risk better than existing tools, offering a potential way to identify high-risk patients missed by current screening criteria.

IUS May Guide Treatment in Children With Ulcerative Colitis

Intestinal ultrasound scan may serve as an early non-invasive predictor of corticosteroid resistance and short-term colectomy in children with acute severe ulcerative colitis.

Routine EHR Data May Help Predict Pancreatic Cancer Risk

A risk model that uses routine clinical data can identify people at high risk of developing pancreatic cancer over the next 3 years.

Can Romiplostim Reduce Chemo Disruptions in GI Cancer?

A recent analysis assesses whether romiplostim can reduce thrombocytopenia-driven chemotherapy dose reductions, delays, and discontinuations.

Tumor Debulking Fails to Boost Survival in Metastatic CRC

Researchers evaluated whether adding tumor debulking to standard palliative systemic therapy improves survival in patients with multiorgan metastatic colorectal cancer in the ORCHESTRA trial.

Analysis-Pediatricians Win Round 1 in Vaccine Fight, but Damage Has Been Done

A federal court injunction on Monday put a check on Health Secretary Robert F. Kennedy Jr.'s rapid assault on U.S. vaccine recommendations, but months of turmoil and...

Tx Delays in CRC More Common in Urban Men, Racial Minorities

A study using data from Surveillance, Epidemiology, and End Results evaluates how sex, race, and geographic disparities affect treatment timeliness in patients with early-onset colorectal cancer.

‘Failure to Thrive’ Now ‘Faltering Weight’ in Pediatrics

The World Health Organization also recommends using a z-score for diagnosing faltering weight, in addition to growth charts.

From Royal Courts to Clinics: How Enemas Evolved

Once considered a universal remedy, enemas are now used selectively for specific clinical indications, such as bowel preparation.

Popular Caraway Oil for Dyspepsia: Benefit or Risk?

Caraway oil is widely used for digestive symptoms; however, strong clinical evidence supports its use in combination with peppermint oil for functional dyspepsia.

Duchenne Gene Therapy Shows Improved Muscle Function in Trial

Regenxbio said on Wednesday that interim data from a early-to-mid stage study of its experimental gene therapy ⁠in patients with Duchenne muscular dystrophy showed continued...

Early Top-Down Therapy Cuts Surgery Risk in Crohn’s

Five-year PROFILE follow-up shows early top-down infliximab-based therapy markedly reduces abdominal surgery and hospitalizations in Crohn’s vs step-up escalation.

Recommended News For You

Since 2000, the outlook for multiple myeloma has improved.

A novel blood test may enable the early identification of common, fatal cancers.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Ketamine plus psychotherapy for "excellent" PTSD

Hereditary cancer has a rare and underreported cause.

Dissociative identity disorder: method or fact?

Recommended Articles For You

The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology 

The Latest Research on Wiskott Aldrich Syndrome  

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program 

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Numerous Oncologists Are Concerned About the Cost of Genomic Testing.

2.

According to new studies, some cancer patients can safely forego radiation therapy.

3.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

4.

Guidelines for cervical cancer screening and the risk of preterm birth in young women.

5.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

1.

Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders

2.

Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance

3.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

4.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

5.

Unveiling the Mystery Behind Lymphovascular Invasion

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

2.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot